Recent Updates
Recently added Catalysts
TAK Positive Sentiment

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Wednesday, September 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Takeda announced promising results from three Phase 3 studies of zasocitinib, a next-generation TYK2 inhibitor for moderate-to-severe plaque psoriasis. The data, presented at the EADV Congress 2026, indicates that zasocitinib outperforms Deucravacitinib in efficacy. This oral medication offers a convenient once-daily dosing regimen, enhancing treatment adherence.

Market Sentiment Analysis

POSITIVE FACTORS

  • Zasocitinib shows superior efficacy compared to Deucravacitinib.
  • Demonstrates potential for rapid and durable skin clearance.
  • Convenient once-daily dosing for patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
SYR-472
Phase 3 · Diabetes Mellitus

Full Press Release Details

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis.1 Presented during late-breaking and oral sessions at the European Academy of Dermatology & Venereology (EADV) Congress 2026, these results demonstrate zasocitinib’s supe

Frequently Asked Questions

What is zasocitinib?

Zasocitinib is an investigational oral TYK2 inhibitor for treating moderate-to-severe plaque psoriasis.

What were the results of the Phase 3 studies?

The studies showed that zasocitinib delivered superior efficacy compared to Deucravacitinib.

How is zasocitinib administered?

Zasocitinib is taken as a convenient once-daily pill.

Where were the results presented?

The results were presented at the European Academy of Dermatology & Venereology Congress 2026.

ShareAdd on Google
Tags: TAK Zasocitinib Deucravacitinib psoriasis TYK2 inhibitor Takeda
Last updated: Sep 30, 2026

Biotech snapshot

Lead asset
SYR-472Phase 3
Diabetes Mellitus →

Catalyst track record

+27%
best trade around TAK's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for TAK.

See every catalyst's timing & PoA →